94 related articles for article (PubMed ID: 2740066)
1. Antiemetic efficacy of escalating doses of alizapride against chemotherapy-induced emesis.
Abad-Esteve A; Rosell R; Moreno I; Serichol M; Moya L; Ribas-Mundo M
Oncology; 1989; 46(4):235-7. PubMed ID: 2740066
[TBL] [Abstract][Full Text] [Related]
2. Alizapride, a new substituted benzamide, as an antiemetic during cancer chemotherapy.
Joss RA; Galeazzi RL; Bischoff AK; Brunner KW
Eur J Clin Pharmacol; 1985; 27(6):721-5. PubMed ID: 3987777
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of a new antiemetic, alizapride, in cancerology (author's transl)].
Cupissol D; Favier F; Favier C; Serrou B
Sem Hop; 1982 Jun; 58(22):1370-3. PubMed ID: 6287597
[TBL] [Abstract][Full Text] [Related]
4. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW
Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041
[TBL] [Abstract][Full Text] [Related]
5. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy.
Niederle N; Schütte J; Schmidt CG
Klin Wochenschr; 1986 Apr; 64(8):362-5. PubMed ID: 3009962
[TBL] [Abstract][Full Text] [Related]
6. [Alizapride: a new antiemetic for severe vomiting during cancer polychemotherapy. Apropos of 20 cases].
Toure P; Ndao D; Wandaogo A; Toure M
Dakar Med; 1984; 29(2):339-42. PubMed ID: 6571252
[No Abstract] [Full Text] [Related]
7. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial.
Bleiberg H; Gerard B; Dalesio O; Crespeigne N; Rozencweig M
Cancer Chemother Pharmacol; 1988; 22(4):316-20. PubMed ID: 3048762
[TBL] [Abstract][Full Text] [Related]
8. High-dose alizapride versus high-dose domperidone: a double-blind comparative study in the management of cis-platinum-induced emesis.
Huys J; Troch M; Bourguignon RP; Smets P
Curr Med Res Opin; 1985; 9(6):400-6. PubMed ID: 3886305
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
Bremer K; Uhlenbusch R
Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
[TBL] [Abstract][Full Text] [Related]
10. [Phase I study of alizapride in cancer patients treated with cisplatin].
Nicaise C; Rozencweig M; Ortmans M; Frisque C; Bleiberg H
Sem Hop; 1983 Sep; 59(31):2161-5. PubMed ID: 6312589
[TBL] [Abstract][Full Text] [Related]
11. Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.
Hulstaert F; Van Belle S; Bleiberg H; Canon JL; Dewitte M; Buyse M; De Keyser P; Westelinck KJ
J Clin Oncol; 1994 Nov; 12(11):2439-46. PubMed ID: 7964961
[TBL] [Abstract][Full Text] [Related]
12. [Antiemetic and antinauseant effect of alizapride in patients subjected to antiblastic infusion chemotherapy in a day-hospital regime].
Cicchetti F; Viganò P; Borghi CM; Franzini A; Alfano G; Antolini C
G Ital Oncol; 1989; 9(1):18-21. PubMed ID: 2707835
[TBL] [Abstract][Full Text] [Related]
13. Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study.
Pollera CF; Nardi M; Marolla P; Calabresi F
Acta Oncol; 1991; 30(6):725-9. PubMed ID: 1958393
[TBL] [Abstract][Full Text] [Related]
14. [Randomized study of the antiemetic efficacy of alizapride versus alizapride + dexamethasone].
Epifani C; Scognamiglio G; Prete C; Alberio F; Gini G; Valli M
G Ital Oncol; 1990; 10(4):115-9. PubMed ID: 2093079
[TBL] [Abstract][Full Text] [Related]
15. [Alizapride in the treatment of vomiting induced by cytostatic agents].
Bierbaum HG
Fortschr Med; 1983 Apr; 101(14):662-4. PubMed ID: 6852737
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of intravenously administered alizapride and prochlorperazine in cisplatin-induced emesis.
Roché H; Hyman G; Nahas G; Stoopler M; Ellison R; Desjardins R
Cancer Invest; 1987; 5(2):89-93. PubMed ID: 3607576
[TBL] [Abstract][Full Text] [Related]
17. [Antiblastic agent-induced vomiting: possibilities of its prevention and alizapride therapy].
Petrella V; Cantone PA; Alciato P; Gagliardini R; Fico D
Minerva Med; 1989 Apr; 80(4):389-92. PubMed ID: 2725942
[TBL] [Abstract][Full Text] [Related]
18. Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study.
Seng KT; Tiong CE; Hiang TC
Br J Clin Pharmacol; 1994 Sep; 38(3):282-4. PubMed ID: 7826833
[TBL] [Abstract][Full Text] [Related]
19. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
20. [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy].
Budach V; Krüger K
Fortschr Med; 1983 Oct; 101(39):1792-4. PubMed ID: 6642386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
